The fecal microbiota transplantation (FMT), as the core therapy strategy for remodeling the gut microbiota adopted generally for a long medical history, has gained a great attention in the world. Though it has been used as a guideline-approved treatment for the recurrent Clostridium difficile infection and a potential option for microbiota-related diseases, the FMT has not been used very well world widely mainly due to the methodology limitation. The fmtBank is a non-profit institute in China, with its core based on the technology system of the FMT. This paper mainly focuses on the medical history, the methodology system of the non-profit fmtBank, and the safety, the ethical problem, the policy and the future direction of the FMT.

fecal microbiota transplantation  /  fmtBank  /  Clostridium difficile